All Articles tagged cost-utility

• Other Conditions
  February 01, 2024 EDT
  Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease
  Adrian PeacockFrances C. DehleOscar A. Mesa ZapataFrancesca GennariMaro R.I. WilliamsNada HamadStephen LarsenSimon J. HarrisonColman Taylor

  The aim of this study was to assess the cost-effectiveness of extracorporeal photopheresis compared with standard-of-care therapies for the treatment of chronic graft-vs-host disease in Australia.

  Abstract
• Cardiovascular Conditions
  November 22, 2022 EDT
  Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
  Carlos AguiarFrancisco AraujoGabriel Rubio-MercadeDavid CarcedoSilvia PazJose María CastellanoValentín Fuster

  We assessed the cost-effectiveness of a cardiovascular polypill strategy compared with the loose combination of monocomponents in controlling cardiovascular risk factors in patients with previous coronary heart disease or stroke.

  Abstract
• Cardiovascular Conditions
  October 26, 2016 EDT
  Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
  Yaariv KhaykinPeter J. MallowJohn A. RizzoAtul VermaLauren ChunShelby OlesovskyMatthew R. Reynolds

  We assess the cost-effectiveness of catheter ablation compared to anti-arrhythmic drug therapy for atrial fibrillation based on community practice.

  Abstract
• Oncology
  October 21, 2015 EDT
  Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
  Gabriel TremblayUnnati MajethiaIlias KontoudisJesús De Rosendo

  We compare the cost-effectiveness of eribulin in Spain as a second-line treatment for HER2-negative MBC with its current status as a third-line treatment for patients who have received capecitabine.

  Abstract
• Gastrointestinal Conditions
  May 06, 2015 EDT
  Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
  Anke van EngenMontserrat CasamayorFidelma LoftusMartin CoenAndy GarnhamMaureen WattLarry Lacey

  To perform a cost-utility analysis of fidaxomicin compared to oral metronidazole and oral vancomycin for the treatment of Clostridium difficile infection.

  Abstract